Revvity, Inc. (NYSE:RVTY) Holdings Decreased by First National Advisers LLC

First National Advisers LLC decreased its holdings in shares of Revvity, Inc. (NYSE:RVTY) by 35.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,238 shares of the company’s stock after selling 5,685 shares during the quarter. First National Advisers LLC’s holdings in Revvity were worth $1,143,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Victory Capital Management Inc. grew its stake in Revvity by 17.4% in the fourth quarter. Victory Capital Management Inc. now owns 70,250 shares of the company’s stock valued at $7,841,000 after purchasing an additional 10,390 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Revvity by 13.7% in the third quarter. JPMorgan Chase & Co. now owns 344,115 shares of the company’s stock valued at $43,961,000 after purchasing an additional 41,497 shares in the last quarter. Contravisory Investment Management Inc. grew its stake in Revvity by 1,715.9% in the fourth quarter. Contravisory Investment Management Inc. now owns 69,186 shares of the company’s stock valued at $7,722,000 after purchasing an additional 65,376 shares in the last quarter. FMR LLC grew its stake in Revvity by 40.8% in the third quarter. FMR LLC now owns 155,556 shares of the company’s stock valued at $19,872,000 after purchasing an additional 45,040 shares in the last quarter. Finally, Janney Montgomery Scott LLC grew its stake in Revvity by 87.0% in the fourth quarter. Janney Montgomery Scott LLC now owns 7,891 shares of the company’s stock valued at $881,000 after purchasing an additional 3,672 shares in the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RVTY. Sanford C. Bernstein downgraded Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 target price on the stock. in a research note on Friday, January 10th. Raymond James restated an “outperform” rating and issued a $145.00 target price (up previously from $140.00) on shares of Revvity in a research note on Monday, February 3rd. KeyCorp boosted their target price on Revvity from $132.00 to $145.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Barclays upped their price target on Revvity from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Finally, Bank of America upgraded Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price target for the company in a research note on Friday, December 13th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Revvity has an average rating of “Moderate Buy” and a consensus price target of $136.25.

Revvity Price Performance

NYSE RVTY opened at $112.13 on Monday. Revvity, Inc. has a twelve month low of $97.32 and a twelve month high of $129.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. The stock has a market capitalization of $13.47 billion, a PE ratio of 50.74, a P/E/G ratio of 3.82 and a beta of 1.06. The stock has a 50-day simple moving average of $117.01 and a 200 day simple moving average of $117.93.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, beating the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period in the previous year, the business posted $1.25 earnings per share. Research analysts anticipate that Revvity, Inc. will post 4.94 EPS for the current year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Thursday, April 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.25%. Revvity’s dividend payout ratio is currently 12.67%.

Insider Activity

In related news, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the sale, the insider now directly owns 33,400 shares in the company, valued at $4,232,782. This represents a 31.23 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Tajinder S. Vohra sold 5,492 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total value of $641,520.52. Following the sale, the insider now owns 19,652 shares in the company, valued at approximately $2,295,550.12. This trade represents a 21.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.60% of the company’s stock.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.